Bristol-Myers Squibb (BMY) Stock Price & Analysis

BMY$63.43+1.11 +1.78%
Drug Manufacturers - GeneralLarge CapValue StockHigh Quality
Compare
Market cap$129.66BEnterprise value$166.45BRevenue (TTM)$50.03BMarket positionTop 25%

Score

61
Neutral
Value
64
Quality
72
Growth
47

AI Analysis

Snapshot

Bristol-Myers Squibb reads as an income name — Stocklytics 61/100, with a 3.9% dividend yield in the thesis. Under the hood: P/E 14.2, about 35% below its own multi-year median, plus 3.9% dividend yield.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

64
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

47
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

72
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Bristol-Myers Squibb Company (BMY) last printed $63.43. Equity value is $129.66B. Trailing earnings multiple 14.03. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$19.43B$20.78B$22.56B$26.14B$42.52B$46.38B$46.16B$45.01B$48.3B$48.2B

About

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Bristol-Myers Squibb (BMY) Stock Price & Analysis

BMY price $63.43 +1.11 +1.78%

Ticker
BMY
Price
$63.43
Change
+1.11 +1.78%
Market cap
$129.66B
P/E
14.03
Forward P/E
9.84
Dividend yield
3.93%
Beta
0.23
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
61
Value
64
Quality
72
Growth
47

Stocklytics score rationale: value 64, quality 72, growth 47.

AI Score 75. Bristol-Myers Squibb has a strong market cap of $127.71 billion and a solid net profit margin of approximately 18.5%, indicating good profitability. However, its high price-to-earnings ratio of about 13.82 and a price-to-book ratio of 5.45 suggest that it may be overvalued relative to its earnings and assets, which could limit upside potential

Summary

Bristol-Myers Squibb Company operates in Healthcare, within the Drug Manufacturers - General industry. Its overall score is 59.

Valuation

The shares have a P/E of 13.8 and a price-to-book ratio of 5.5. The value score is 64.

Quality

The quality score is 67, supported by a net margin of 18.5%. The dividend yield is 4.0%.

Growth

The growth score is 46, indicating growth is the weakest of the reported factor scores.

Risks

Growth is a relative concern given the growth score of 46. The price-to-book ratio of 5.5 may also be relevant when assessing valuation.

Fair value

BMY fair value $133.71. Price $63.43. Price is 53% below fair value.

Below fair value, but more expensive than usual. A smaller discount than on 77% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 28.3, a blend of the Drug Manufacturers - General median (35.7) and the stock's own 10-year median (20.8). How we calculate it →

Compare BMY

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-04—1.53—12.66B
2026-10-291.351.1013.07B12.72B
2026-07-302.041.6012.97B11.74B
2026-04-301.581.4211.49B10.93B
2026-02-051.261.2312.50B12.28B
2025-10-301.631.5212.22B11.85B
2025-07-311.461.0912.27B11.44B
2025-04-241.801.4911.20B10.70B
2025-02-061.671.4712.34B11.57B
2024-10-311.801.4911.89B11.26B
2024-07-262.071.6212.20B11.54B
2024-04-25-4.40-4.4111.87B11.48B
2024-02-021.701.5211.48B11.19B
2023-10-262.001.7610.97B10.97B
2023-07-271.751.9911.23B11.80B
2023-04-272.051.9811.34B11.49B
2023-02-021.821.7111.41B11.19B
2022-10-251.991.8311.22B11.14B
2022-07-271.931.7911.89B11.42B
2022-04-291.961.9211.65B11.36B
2022-02-041.831.8311.98B12.04B
2021-10-272.001.9111.62B11.63B
2021-07-281.931.8811.70B11.61B
2021-04-291.741.8011.07B11.56B
2021-02-041.461.3711.07B10.68B
2020-11-051.631.4910.54B9.63B
2020-08-061.631.4610.13B9.20B
2020-05-071.721.4810.78B9.34B
2020-02-061.221.307.95B5.73B
2019-10-311.171.066.01B5.49B
2019-07-251.181.066.27B5.69B
2019-04-251.101.095.92B5.87B
2019-01-240.940.855.97B5.40B
2018-10-251.090.915.69B4.75B
2018-07-261.010.875.70B4.91B
2018-04-260.940.855.19B4.70B
2018-02-050.680.675.45B5.37B
2017-10-260.750.775.25B5.39B
2017-07-270.740.735.14B5.14B
2017-04-270.840.744.93B4.34B

Dividends

Yield 3.97%. Payout ratio 55.38%. Frequency Quarterly.

Safety score 89/100 · Safe. Payout ratio is 55% of earnings. Dividends use less than 40% of free cash flow. Dividends were paid in 55 separate years. Yield is 4.0%, in a range that is usually sustainable.

Ex-dateDividendRecordPaymentFrequency
2026-10-02$0.632026-10-022026-11-02Quarterly
2026-07-02$0.632026-07-022026-08-03Quarterly
2026-04-02$0.632026-04-022026-05-01Quarterly
2026-01-02$0.632026-01-022026-02-02Quarterly
2025-10-03$0.622025-10-032025-11-03Quarterly
2025-07-03$0.622025-07-032025-08-01Quarterly
2025-04-04$0.622025-04-042025-05-01Quarterly
2025-01-03$0.622025-01-032025-02-03Quarterly
2024-10-04$0.602024-10-042024-11-01Quarterly
2024-07-05$0.602024-07-052024-08-01Quarterly
2024-04-04$0.602024-04-052024-05-01Quarterly
2024-01-04$0.602024-01-052024-02-01Quarterly
2023-10-05$0.572023-10-062023-11-01Quarterly
2023-07-06$0.572023-07-072023-08-01Quarterly
2023-04-06$0.572023-04-102023-05-01Quarterly
2023-01-05$0.572023-01-062023-02-01Quarterly
2022-10-06$0.542022-10-072022-11-01Quarterly
2022-06-30$0.542022-07-012022-08-01Quarterly
2022-03-31$0.542022-04-012022-05-02Quarterly
2022-01-06$0.542022-01-072022-02-01Quarterly
2021-09-30$0.492021-10-012021-11-01Quarterly
2021-07-01$0.492021-07-022021-08-02Quarterly
2021-03-31$0.492021-04-012021-05-03Quarterly
2020-12-31$0.492021-01-042021-02-01Quarterly
2020-10-01$0.452020-10-022020-11-02Quarterly
2020-07-02$0.452020-07-062020-08-03Quarterly
2020-04-02$0.452020-04-032020-05-01Quarterly
2020-01-02$0.452020-01-032020-02-03Quarterly
2019-10-03$0.412019-10-042019-11-01Quarterly
2019-07-03$0.412019-07-052019-08-01Quarterly
2019-04-04$0.412019-04-052019-05-01Quarterly
2019-01-03$0.412019-01-042019-02-01Quarterly
2018-10-04$0.402018-10-052018-11-01Quarterly
2018-07-05$0.402018-07-062018-08-01Quarterly
2018-04-05$0.402018-04-062018-05-01Quarterly
2018-01-04$0.402018-01-052018-02-01Quarterly
2017-10-05$0.392017-10-062017-11-01Quarterly
2017-07-05$0.392017-07-072017-08-01Quarterly
2017-04-05$0.392017-04-072017-05-01Quarterly
2017-01-04$0.392017-01-062017-02-01Quarterly
2016-10-05$0.382016-10-072016-11-01Quarterly
2016-06-29$0.382016-07-012016-08-01Quarterly
2016-03-30$0.382016-04-012016-05-02Quarterly
2015-12-30$0.382016-01-042016-02-01Quarterly
2015-09-30$0.372015-10-022015-11-02Quarterly
2015-07-01$0.372015-07-062015-08-03Quarterly
2015-04-01$0.372015-04-062015-05-01Quarterly
2014-12-30$0.372015-01-022015-02-02Quarterly
2014-10-01$0.362014-10-032014-11-03Quarterly
2014-07-01$0.362014-07-032014-08-01Quarterly
2014-04-02$0.362014-04-042014-05-01Quarterly
2013-12-31$0.362014-01-032014-02-03Quarterly
2013-10-02$0.352013-10-042013-11-01Quarterly
2013-07-02$0.352013-07-052013-08-01Quarterly
2013-04-03$0.352013-04-052013-05-01Quarterly
2013-01-02$0.352013-01-042013-02-01Quarterly
2012-10-03$0.342012-10-052012-11-01Quarterly
2012-07-03$0.342012-07-062012-08-01Quarterly
2012-04-03$0.342012-04-052012-05-01Quarterly
2012-01-04$0.342012-01-062012-02-01Quarterly
2011-10-06$0.332011-10-112011-11-01Quarterly
2011-06-29$0.332011-07-012011-08-01Quarterly
2011-03-30$0.332011-04-012011-05-02Quarterly
2011-01-05$0.332011-01-072011-02-01Quarterly
2010-09-29$0.322010-10-012010-11-01Quarterly
2010-06-30$0.322010-07-022010-08-02Quarterly
2010-03-30$0.322010-04-042010-05-03Quarterly
2009-12-30$0.322010-01-042010-02-01Quarterly
2009-09-30$0.312009-10-022009-11-02Quarterly
2009-07-01$0.312009-07-062009-08-03Quarterly
2009-04-01$0.312009-04-032009-05-01Quarterly
2008-12-30$0.312009-01-022009-02-02Quarterly
2008-10-01$0.312008-10-032008-11-03Quarterly
2008-07-02$0.312008-07-072008-08-01Quarterly
2008-04-02$0.312008-04-042008-05-01Quarterly
2008-01-02$0.312008-01-042008-02-01Quarterly
2007-10-03$0.282007-10-052007-11-01Quarterly
2007-07-03$0.282007-07-062007-08-01Quarterly
2007-04-03$0.282007-04-062007-05-01Quarterly
2007-01-03$0.282007-01-052007-02-01Quarterly

Insider trades

DateInsiderActionSharesPriceValue
2026-11-05Haller Julia ASell3.80K$63.31240.58K
2026-11-03Lenkowsky AdamBuy7.52K——
2026-11-03Lenkowsky AdamSell3.85K$61.71237.46K
2026-11-03Lenkowsky AdamSell7.52K——
2026-11-01BOERNER CHRISTOPHER S.Buy406——
2026-11-01BOERNER CHRISTOPHER S.Buy2.96K——
2026-11-01BOERNER CHRISTOPHER S.Sell1.72K$62.48107.72K
2026-11-01BOERNER CHRISTOPHER S.Sell2.96K——
2026-11-01Shanahan KarinBuy6.28K——
2026-11-01Shanahan KarinSell3.21K$62.48200.75K
2026-11-01Shanahan KarinSell6.28K——
2026-11-01Meyers Gregory ScottBuy6.28K——
2026-11-01Meyers Gregory ScottSell2.67K$62.48166.51K
2026-11-01Meyers Gregory ScottSell6.28K——
2026-10-02Gallman CariBuy4.56K——
2026-10-02Gallman CariSell2.33K$61.15142.60K
2026-10-02Gallman CariSell4.56K——
2026-09-30YALE PHYLLIS RBuy561$62.4035.00K
2026-09-30Samuels Theodore R. IIBuy821$62.4051.25K
2026-09-30Rice Derica WBuy621$62.4038.75K
2026-09-30McMullen Michael R.Buy561——
2026-09-30Arduini Peter JBuy561——
2026-09-09Massacesi CristianSell6.25K$64.57403.50K
2026-09-01Short Bartie WendyBuy1.24K$66.9282.71K
2026-09-01Short Bartie WendySell633$66.9242.36K
2026-09-01Short Bartie WendySell1.24K——
2026-08-25Holzer Phil MSell500$67.5033.75K
2026-08-01Massacesi CristianSell51.17K——
2026-08-01Massacesi CristianBuy51.17K——
2026-08-01Massacesi CristianSell26.18K$65.311.71M
2026-08-01Gallman CariBuy1.06K——
2026-08-01Gallman CariSell543$65.3135.46K
2026-08-01Gallman CariSell1.06K——
2026-06-30YALE PHYLLIS RBuy607——
2026-06-30Samuels Theodore R. IIBuy889——
2026-06-30Rice Derica WBuy673——
2026-06-30McMullen Michael R.Buy607——
2026-06-30Arduini Peter JBuy607——
2026-06-15Haller Julia ABuy20.46K$53.761.10M
2026-06-15Haller Julia ASell20.46K$53.761.10M
2026-06-03Short Bartie WendyBuy8.04K——
2026-06-03Short Bartie WendySell3.88K$54.72212.09K
2026-06-03Short Bartie WendySell8.04K——
2026-05-01Lenkowsky AdamBuy1.37K——
2026-05-01Lenkowsky AdamSell203——
2026-05-01Lenkowsky AdamSell599$58.2234.87K
2026-05-01Lenkowsky AdamSell1.37K——
2026-04-01Shanahan KarinBuy3.31K——
2026-04-01Shanahan KarinSell1.69K$61.73104.45K
2026-04-01Shanahan KarinSell3.31K——
2026-04-01Elkins David VSell25.52K$61.601.57M
2026-04-01Elkins David VSell4.48K$62.05278.05K
2026-03-31YALE PHYLLIS RBuy577——
2026-03-31Samuels Theodore R. IIBuy845——
2026-03-31Rice Derica WBuy639——
2026-03-31McMullen Michael R.Buy577——
2026-03-31Arduini Peter JBuy577——
2026-03-10Hickey BenjaminBuy17.14K——
2026-03-10Hickey BenjaminBuy11.43K——
2026-03-10Shibutani Hiroshi ChrisBuy11.76K——
2026-03-10Shibutani Hiroshi ChrisBuy7.84K——
2026-03-10Massacesi CristianBuy39.18K——
2026-03-10Massacesi CristianBuy26.12K——
2026-03-10Short Bartie WendyBuy4.50K——
2026-03-10Short Bartie WendyBuy9.80K——
2026-03-10Short Bartie WendySell2.21K——
2026-03-10Short Bartie WendySell828$60.1349.79K
2026-03-10Short Bartie WendyBuy749——
2026-03-10Short Bartie WendySell81——
2026-03-10Short Bartie WendyBuy6.53K——
2026-03-10Short Bartie WendySell242$60.1314.55K
2026-03-10Short Bartie WendyBuy639——
2026-03-10Short Bartie WendySell72——
2026-03-10Short Bartie WendySell205$60.1312.33K
2026-03-10Short Bartie WendySell749——
2026-03-10Short Bartie WendySell639——
2026-03-10Short Bartie WendySell4.50K——
2026-03-10Shanahan KarinBuy19.76K——
2026-03-10Shanahan KarinBuy31.84K——
2026-03-10Shanahan KarinSell9.70K——
2026-03-10Shanahan KarinSell5.14K$60.13309.37K
2026-03-10Shanahan KarinBuy21.22K——
2026-03-10Shanahan KarinBuy3.29K——
2026-03-10Shanahan KarinSell356——
2026-03-10Shanahan KarinSell1.50K$60.1390.38K
2026-03-10Shanahan KarinBuy2.45K——
2026-03-10Shanahan KarinSell275——
2026-03-10Shanahan KarinSell1.11K$60.1366.86K
2026-03-10Shanahan KarinSell3.29K——
2026-03-10Shanahan KarinSell2.45K——
2026-03-10Shanahan KarinSell19.76K——
2026-03-10Plenge Robert MBuy14.05K——
2026-03-10Plenge Robert MBuy26.94K——
2026-03-10Plenge Robert MSell6.90K——
2026-03-10Plenge Robert MSell3.17K$60.13190.73K
2026-03-10Plenge Robert MBuy2.34K——
2026-03-10Plenge Robert MSell253——
2026-03-10Plenge Robert MBuy17.96K——
2026-03-10Plenge Robert MSell927$60.1355.74K
2026-03-10Plenge Robert MBuy1.11K——

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 2.30K, holders -337 vs prior quarter. Ownership 59.55%.

HolderSharesChangeChange %Value
BLACKROCK, INC.173.66M-6.72M-3.73%10.84B
VANGUARD CAPITAL MANAGEMENT LLC133.69M347.32K+0.26%8.34B
STATE STREET CORP103.34M926.68K+0.90%6.45B
JPMORGAN CHASE & CO60.22M-11.50M-16.03%3.79B
GEODE CAPITAL MANAGEMENT, LLC50.64M-5.80M-10.28%3.15B
VANGUARD PORTFOLIO MANAGEMENT LLC47.06M188.96K+0.40%2.94B
MORGAN STANLEY28.38M-629.28K-2.17%1.77B
FMR LLC28.32M12.02M+73.80%1.77B
PRIMECAP MANAGEMENT CO/CA/25.20M275.83K+1.11%1.57B
INDEPENDENT FRANCHISE PARTNERS LLP21.54M-254.21K-1.17%1.34B
DIMENSIONAL FUND ADVISORS LP20.05M353.64K+1.80%1.25B
BANK OF NEW YORK MELLON CORP19.85M-1.97M-9.03%1.24B
INVESCO LTD.18.27M2.23M+13.93%1.14B
PZENA INVESTMENT MANAGEMENT LLC14.24M-2.76M-16.24%888.88M
ACADIAN ASSET MANAGEMENT LLC12.30M709.62K+6.12%767.66M
VANGUARD FIDUCIARY TRUST CO11.53M63.94K+0.56%719.58M
DEUTSCHE BANK AG\10.78M632.94K+6.24%672.43M
VICTORY CAPITAL MANAGEMENT INC10.69M525.02K+5.16%667.30M
NORDEA INVESTMENT MANAGEMENT AB9.62M1.57M+19.44%613.70M
AMUNDI9.67M2.20M+29.43%603.67M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP9.63M1.04M+12.14%600.80M
LSV ASSET MANAGEMENT9.50M-354.69K-3.60%592.65M
VAN ECK ASSOCIATES CORP8.29M-1.93M-18.89%517.16M
JANE STREET GROUP, LLC7.31M7.31MNew455.84M
ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.7.20M-44.33K-0.61%449.30M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener